MX2009013393A - Expresion de fragmento de anticuerpo soluble mediante truncamiento de dominio de ch1. - Google Patents

Expresion de fragmento de anticuerpo soluble mediante truncamiento de dominio de ch1.

Info

Publication number
MX2009013393A
MX2009013393A MX2009013393A MX2009013393A MX2009013393A MX 2009013393 A MX2009013393 A MX 2009013393A MX 2009013393 A MX2009013393 A MX 2009013393A MX 2009013393 A MX2009013393 A MX 2009013393A MX 2009013393 A MX2009013393 A MX 2009013393A
Authority
MX
Mexico
Prior art keywords
truncation
expression
fragment
light chain
chi
Prior art date
Application number
MX2009013393A
Other languages
English (en)
Inventor
Jon C Mitchell
Diane Retallack
Original Assignee
Dow Global Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc filed Critical Dow Global Technologies Inc
Publication of MX2009013393A publication Critical patent/MX2009013393A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Abstract

La expresión mejorada de fragmentos de anticuerpos activos (Fabs) es lograda al truncar una región constante de cadena pesada. El truncamiento del dominio CHI de un fragmento Fab puede aumentar el rendimiento de fragmento de anticuerpo activo soluble en Pseudomonas fluorescens. Otra modalidad de la invención incluye la secreción de la cadena ligera y un fragmento de la cadena pesada con varios extremos C (por ejemplo, VH-Cl truncado a diferentes longitudes). La región CHI truncada puede ser usada como un andamiaje para crear otros Fabs. También se incluye el truncamiento de los dominios de cadena ligera kappa y/o cadena ligera lambda de un fragmento Fab. La invención también incluye la expresión de fragmentos Fab fusionados a otros péptidos o moléculas (por ejemplo toxinas, proteínas, péptidos, enzimas, etc.).
MX2009013393A 2007-06-08 2008-06-06 Expresion de fragmento de anticuerpo soluble mediante truncamiento de dominio de ch1. MX2009013393A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94299707P 2007-06-08 2007-06-08
PCT/US2008/066187 WO2008151319A2 (en) 2007-06-08 2008-06-06 Expression of soluble antibody fragment by truncation of ch1 domain

Publications (1)

Publication Number Publication Date
MX2009013393A true MX2009013393A (es) 2010-02-09

Family

ID=40076617

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013393A MX2009013393A (es) 2007-06-08 2008-06-06 Expresion de fragmento de anticuerpo soluble mediante truncamiento de dominio de ch1.

Country Status (9)

Country Link
US (1) US20090042254A1 (es)
EP (1) EP2160405A2 (es)
JP (1) JP2010528664A (es)
KR (1) KR20100021627A (es)
AU (1) AU2008261042A1 (es)
BR (1) BRPI0812465A2 (es)
CA (1) CA2689556A1 (es)
MX (1) MX2009013393A (es)
WO (1) WO2008151319A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2450366A1 (en) 2007-01-30 2012-05-09 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
LT2954779T (lt) * 2009-12-10 2019-05-27 Regeneron Pharmaceuticals, Inc. Pelės, gaminančios sunkiosios grandinės antikūnus
BR112016004355A2 (pt) * 2013-08-30 2017-10-17 Aprilbio Co Ltd constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
KR20210088756A (ko) 2014-03-21 2021-07-14 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2018211529A1 (en) * 2017-05-19 2018-11-22 Council Of Scientific & Industrial Research A method for producing refolded recombinant humanized ranibizumab
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US9453251B2 (en) * 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
PL1644412T5 (pl) * 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
US20070274985A1 (en) * 2006-05-26 2007-11-29 Stefan Dubel Antibody

Also Published As

Publication number Publication date
US20090042254A1 (en) 2009-02-12
CA2689556A1 (en) 2008-12-11
AU2008261042A1 (en) 2008-12-11
WO2008151319A2 (en) 2008-12-11
WO2008151319A3 (en) 2009-03-26
KR20100021627A (ko) 2010-02-25
BRPI0812465A2 (pt) 2014-12-02
EP2160405A2 (en) 2010-03-10
JP2010528664A (ja) 2010-08-26
AU2008261042A2 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
MX2009013393A (es) Expresion de fragmento de anticuerpo soluble mediante truncamiento de dominio de ch1.
BRPI0517837A (pt) variantes fc com ligação alterada a fcrn
PE20120014A1 (es) Anticuerpos humanos de alta afinidad contra pcsk9
ATE527284T1 (de) Modifizierte antikörper-fragmente
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
MY157173A (en) Modified humanised anti-interleukin-18
CR11298A (es) Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano
MX342413B (es) Anticuerpos para metaloproteinasa-9 de matriz.
EA200870411A1 (ru) Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы
RU2020106752A (ru) Субстраты матриксной металлопротеиназы и другие расщепляемые фрагменты и способы их использования
NZ588457A (en) Humanized anti-factor d antibodies and uses thereof
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
EA201070888A1 (ru) Антитела и их производные
EA200800812A1 (ru) Композиции антитела против cd3
ES2686327T3 (es) Moléculas de unión a antígeno biespecíficas
PE20091351A1 (es) Anticuerpos humanizados especificos para el factor von willebrand
MX2014001799A (es) Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso.